All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA grants fast track and orphan drug designations to VLS-101 for the treatment of patients with MCL

Sep 3, 2020
Share:

On August 31, 2020, the U.S. Food and Drug Administration (FDA) granted fast track and orphan drug designations to VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).1

VLS-101 is an antibody-drug conjugate targeting tyrosine kinase-like orphan receptor 1 (ROR1). A first-in-human, phase I, dose-escalation trial (NCT03833180) is currently investigating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of VLS-101 in patients with relapsed or refractory hematological malignancies, including MCL.

VLS-101 could represent a new therapeutic option for patients with MCL.

  1. Business Wire. VelosBio announces FDA fast track and orphan drug designations for VLS-101 in patients with mantle cell lymphoma. https://www.businesswire.com/news/home/20200831005097/en/VelosBio-Announces-FDA-Fast-Track-Orphan-Drug. Published Aug 31, 2020. Accessed Sep 01, 2020.

Share: